CLM
vs
D
DAX Index
CLM
Over the past 12 months, CLM has underperformed DAX Index, delivering a return of -61% compared to the DAX Index's +10% growth.
Stocks Performance
CLM vs DAX Index
Performance Gap
CLM vs DAX Index
Performance By Year
CLM vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Clearside Biomedical Inc
Glance View
Clearside Biomedical, Inc. is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. The company is headquartered in Alpharetta, Georgia and currently employs 34 full-time employees. The company went IPO on 2016-06-02. The firm is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS). Its SCS injection platform utilizing its SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted delivery of a variety of therapies to the macula, retina or choroid to preserve and improve vision in patients with sight-threatening eye diseases. The company is focused on developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector, and it also partners with companies developing other ophthalmic therapeutics to be administered using its SCS injection platform. Its lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection. Its pipeline includes CLS-AX, CLS-301 and Gene Therapy.
